0R0T Stock Overview
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 4/6 |
Rewards
Risk Analysis
Amgen Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$305.75 |
| 52 Week High | US$329.12 |
| 52 Week Low | US$211.96 |
| Beta | 0.59 |
| 1 Month Change | 11.59% |
| 3 Month Change | -4.90% |
| 1 Year Change | 30.24% |
| 3 Year Change | 20.85% |
| 5 Year Change | 79.43% |
| Change since IPO | 96.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0R0T | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 13.5% | 5.9% | 1.0% |
| 1Y | 30.2% | -26.8% | 3.0% |
Return vs Industry: 0R0T exceeded the UK Biotechs industry which returned -28.8% over the past year.
Return vs Market: 0R0T exceeded the UK Market which returned 3.5% over the past year.
Price Volatility
| 0R0T volatility | |
|---|---|
| 0R0T Average Weekly Movement | 4.3% |
| Biotechs Industry Average Movement | 7.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.4% |
| 10% least volatile stocks in GB Market | 2.7% |
Stable Share Price: 0R0T has not had significant price volatility in the past 3 months.
Volatility Over Time: 0R0T's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1980 | 26,700 | Bob Bradway | www.amgen.com |
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company’s principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet’s disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI.
Amgen Inc. Fundamentals Summary
| 0R0T fundamental statistics | |
|---|---|
| Market cap | US$166.97b |
| Earnings (TTM) | US$3.76b |
| Revenue (TTM) | US$29.53b |
44.4x
P/E Ratio5.7x
P/S RatioIs 0R0T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0R0T income statement (TTM) | |
|---|---|
| Revenue | US$29.53b |
| Cost of Revenue | US$8.74b |
| Gross Profit | US$20.79b |
| Other Expenses | US$17.03b |
| Earnings | US$3.76b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.02 |
| Gross Margin | 70.41% |
| Net Profit Margin | 12.74% |
| Debt/Equity Ratio | 1,274.8% |
How did 0R0T perform over the long term?
See historical performance and comparisonDividends
2.9%
Current Dividend Yield123%
Payout RatioDoes 0R0T pay a reliable dividends?
See 0R0T dividend history and benchmarks| Amgen dividend dates | |
|---|---|
| Ex Dividend Date | May 16 2024 |
| Dividend Pay Date | Jun 07 2024 |
| Days until Ex dividend | 12 days |
| Days until Dividend pay date | 34 days |
Does 0R0T pay a reliable dividends?
See 0R0T dividend history and benchmarks